Sobi Licenses Lacutamab in $580 Million Deal

Company: Innate Pharma · Event Type: Deal and Financing · Product/Asset: lacunamab · Subject: Cutaneous T-Cell Lymphoma · Event Date: August 10, 2026 Summary Innate Pharma and Sobi entered a licensing partnership for lacutamab in cutaneous T-cell lymphoma (CTCL). Sobi will pay $75 million at…